1.85
-0.07(-3.65%)
Currency In USD
| Previous Close | 1.92 |
| Open | 1.92 |
| Day High | 1.94 |
| Day Low | 1.82 |
| 52-Week High | 8.9 |
| 52-Week Low | 1.73 |
| Volume | 591,096 |
| Average Volume | 1.16M |
| Market Cap | 181.18M |
| PE | -1.08 |
| EPS | -1.71 |
| Moving Average 50 Days | 3.81 |
| Moving Average 200 Days | 4.92 |
| Change | -0.07 |
If you invested $1000 in Alector, Inc. (ALEC) since IPO date, it would be worth $102.32 as of December 26, 2024 at a share price of $1.85. Whereas If you bought $1000 worth of Alector, Inc. (ALEC) shares 3 years ago, it would be worth $81.79 as of December 26, 2024 at a share price of $1.85.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer’s Disease and Provides Business Update
GlobeNewswire Inc.
Nov 25, 2024 9:05 PM GMT
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the treatment of neurodegenerative diseases, today announced r
Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital
GlobeNewswire Inc.
Nov 14, 2024 9:05 PM GMT
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the Company has entered into a debt financing agreement with Hercu
Alector Reports Third Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire Inc.
Nov 06, 2024 9:05 PM GMT
Data from INVOKE-2, evaluating TREM2 agonist candidate AL002 in patients with early Alzheimer’s disease (AD), on track for 2024 Participant baseline characteristics in pivotal INFRONT-3 Phase 3 trial suggest a representative study population for test